The purpose of this proof of concept study is to find out the efficacy of Marealis Refined Peptide Concentrate (RPC) from Coldwater Shrimp (Pandalus borealis) containing ACE-inhibiting peptides on blood pressure in subjects with mild or moderate hypertension.

Inclusion Criteria:

• mild or moderate hypertension (systolic blood pressure 130 - 160 mmHg and diastolic blood pressure ≤ 100 mmHg)
• age 30 - 75 years
• body weight ≥ 60 kg
• stable body weight
• use of effective contraception in women of childbearing potential

Exclusion Criteria:

• body mass index ≥ 35
• antihypertensive drug treatment, regular high dose NSAID treatment and the use of cyclosporine or tacrolimus
• diabetes (type 1 and 2)
• anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid function, clinically significant biochemistry, any other clinically significant hematology and/or biochemistry at the investigator's discretion
• cardiovascular disease (myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening) including stroke and congestive heart failure
• secondary hypertension history of cancer or malignant disease within the past five years
• any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subjects
• fish and other seafood allergies, citrus allergy, multiple food allergies
• alcohol abuse
• smokers and tobacco/snuff/nicotine users
• consumption of food supplements targeted to blood pressure lowering within 30 days before randomization
• pregnant and lactating mothers, women, planning for pregnancy during the study
• participation in clinical trials 30 days prior to this study and participation in other clinical intervention